225 related articles for article (PubMed ID: 19539572)
1. Regulatory T cells and EBV associated malignancies.
Li J; Qian CN; Zeng YX
Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.
Masmoudi A; Toumi N; Khanfir A; Kallel-Slimi L; Daoud J; Karray H; Frikha M
Cancer Treat Rev; 2007 Oct; 33(6):499-505. PubMed ID: 17544585
[TBL] [Abstract][Full Text] [Related]
5. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
6. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
7. EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies.
Yuling H; Ruijing X; Li L; Xiang J; Rui Z; Yujuan W; Lijun Z; Chunxian D; Xinti T; Wei X; Lang C; Yanping J; Tao X; Mengjun W; Jie X; Youxin J; Jinquan T
Cancer Res; 2009 Oct; 69(20):7935-44. PubMed ID: 19808969
[TBL] [Abstract][Full Text] [Related]
8. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
9. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
11. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
[TBL] [Abstract][Full Text] [Related]
12. [Hodgkin's disease and Epstein-Barr virus].
Depil S; Moralès O; Auriault C
Ann Biol Clin (Paris); 2004; 62(6):639-48. PubMed ID: 15563422
[TBL] [Abstract][Full Text] [Related]
13. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma.
Ambinder RF; Robertson KD; Moore SM; Yang J
Semin Cancer Biol; 1996 Aug; 7(4):217-26. PubMed ID: 8946606
[TBL] [Abstract][Full Text] [Related]
15. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma.
Marshall NA; Culligan DJ; Tighe J; Johnston PW; Barker RN; Vickers MA
Exp Hematol; 2007 Apr; 35(4):596-604. PubMed ID: 17379070
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus and Hodgkin's lymphoma.
Andersson J
Herpes; 2006 May; 13(1):12-6. PubMed ID: 16732997
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-associated Hodgkin's lymphoma.
Gandhi MK; Tellam JT; Khanna R
Br J Haematol; 2004 May; 125(3):267-81. PubMed ID: 15086409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
